<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6926">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972777</url>
  </required_header>
  <id_info>
    <org_study_id>603</org_study_id>
    <nct_id>NCT00972777</nct_id>
  </id_info>
  <brief_title>Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis</brief_title>
  <official_title>A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the clinical and microbial efficacy of
      besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial
      conjunctivitis. This study was conducted as a phase IIb study and continued with further
      enrollment as a phase III study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Resolution</measure>
    <time_frame>Visit 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of both conjunctival discharge and bulbar conjunctival injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbial Eradication</measure>
    <time_frame>Visit 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution</measure>
    <time_frame>Visit 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of both conjunctival discharge and bulbar conjunctival injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial Eradication</measure>
    <time_frame>Visit 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">474</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Besifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6% ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifloxacin</intervention_name>
    <description>Besifloxacin 0.6% administered into the study eye two times a day for three days.</description>
    <arm_group_label>Besifloxacin</arm_group_label>
    <other_name>Besivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle (Placebo)</intervention_name>
    <description>Vehicle administered to the study eye two times a day for three days.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are at least one year of age.

          -  Subjects who have a clinical diagnosis of acute bacterial conjunctivitis.

          -  Subjects who are willing to discontinue contact lens wear for the duration of the
             study.

        Exclusion Criteria:

          -  Subjects who have any uncontrolled systemic disease or debilitating disease.

          -  Subjects with known sensitivity or contraindications to besifloxacin,
             fluoroquinolones or any ingredients in study drugs.

          -  Subjects who are expected to require treatment with any disallowed medications.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Paterno, OD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <lastchanged_date>February 14, 2012</lastchanged_date>
  <firstreceived_date>September 4, 2009</firstreceived_date>
  <firstreceived_results_date>January 12, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Besifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a two phase (IIB/III) integrated study. Phase IIb was conducted at 31 sites and Phase III at 28 sites in the United States. The first participant was enrolled in phase IIb on 10/30/2009, and last participant exited the study on 04/09/2010. Phase III enrolled its first participant on 04/05/2010 and last participant exited on 10/13/2010.</recruitment_details>
      <pre_assignment_details>A total of 474 participants were enrolled in the integrated study in the intent to treat(ITT) population. 276 participants had culture confirmed bacterial conjunctivitis and were assigned to the modified intent to treat(mITT) population. 464 participants were assigned to the safety population. 446 participants completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Besifloxacin</title>
          <description>0.6% ophthalmic suspension</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of besifloxacin ophthalmic suspension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Besifloxacin</title>
          <description>0.6% ophthalmic suspension</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of besifloxacin ophthalmic suspension</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="231"/>
                <measurement group_id="B2" value="243"/>
                <measurement group_id="B3" value="474"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;2 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>2 - 11 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="77"/>
                <measurement group_id="B3" value="143"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>12 - 17 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>18 - 29 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>30 - 39 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>40 - 49 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="37"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>50 - 59 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=60 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="66"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="142"/>
                <measurement group_id="B2" value="133"/>
                <measurement group_id="B3" value="275"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
                <measurement group_id="B2" value="110"/>
                <measurement group_id="B3" value="199"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="103"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="167"/>
                <measurement group_id="B2" value="166"/>
                <measurement group_id="B3" value="333"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Resolution</title>
        <description>The absence of both conjunctival discharge and bulbar conjunctival injection.</description>
        <time_frame>Visit 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>Clinical Resolution at Visit 2, (LOCF), mITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Besifloxacin</title>
            <description>0.6% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of besifloxacin ophthalmic suspension</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Resolution</title>
            <description>The absence of both conjunctival discharge and bulbar conjunctival injection.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Microbial Eradication</title>
        <description>The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.</description>
        <time_frame>Visit 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbial Eradication at Visit 2, (LOCF), mITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Besifloxacin</title>
            <description>0.6% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of besifloxacin ophthalmic suspension</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Microbial Eradication</title>
            <description>The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Resolution</title>
        <description>The absence of both conjunctival discharge and bulbar conjunctival injection.</description>
        <time_frame>Visit 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Clinical Resolution at Visit 3, (LOCF) mITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Besifloxacin</title>
            <description>0.6% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of besifloxacin ophthalmic suspension</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Resolution</title>
            <description>The absence of both conjunctival discharge and bulbar conjunctival injection.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103"/>
                  <measurement group_id="O2" value="94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbial Eradication</title>
        <description>The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.</description>
        <time_frame>Visit 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Microbial Eradication at Visit 3, (LOCF), mITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Besifloxacin</title>
            <description>0.6% ophthalmic suspension</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of besifloxacin ophthalmic suspension</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="135"/>
                  <measurement group_id="O2" value="141"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Microbial Eradication</title>
            <description>The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.</description>
            <units>eyes</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="115"/>
                  <measurement group_id="O2" value="91"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <desc>Safety Population, participants receiving at least one drop of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Besifloxacin</title>
          <description>0.6% ophthalmic suspension</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of besifloxacin ophthalmic suspension</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by the Sponsor or its designee and the Investigator(s) are completed. The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tuyen Ong, MD, MRCOphth</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(973) 360-6389</phone>
      <email>tuyen.ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
